Excel PharmaStudies Chairman Mark Engel On China’s Rapidly Expanding Clinical Trials: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
BEIJING - Excel PharmaStudies, established in 2000, is one of the leading clinical research organizations in China. Excel PharmaStudies Chairman Mark Engel recently talked with PharmAsia News' Beijing bureau about China's pharmaceutical market and the role of clinical trials in China. In the second part of this interview, below, Engel talks about recent develops that could drive more trials to China, including a new law enacted last year in the U.S.
You may also be interested in...
CROs in Asian Giants India and China Create Alliance To Conduct Clinical Trials To Keep Pace With Exploding Demand
BEIJING - In response to rapidly accelerating demand for clinical drug research across Asia, India's GVK Biosciences and China's Excel PharmaStudies are crafting an alliance to jointly conduct trials in both countries
CROs in Asian Giants India and China Create Alliance To Conduct Clinical Trials To Keep Pace With Exploding Demand
BEIJING - In response to rapidly accelerating demand for clinical drug research across Asia, India's GVK Biosciences and China's Excel PharmaStudies are crafting an alliance to jointly conduct trials in both countries
Excel PharmaStudies Chairman Mark Engel On China’s Rapidly Expanding Clinical Trials: An Interview With PharmAsia News (Part 1 of 2)
BEIJING - Excel PharmaStudies, established in 2000, is one of the leading clinical research organizations in China. Excel PharmaStudies Chairman Mark Engel recently talked with PharmAsia News' Beijing bureau about the high-speed development of China's pharmaceutical market and the role of clinical trials in China. Engel also outlined challenges, solutions and opportunities regarding clinical trials in China.